原発性肺癌における組織型とdynamic CTの造影効果の関連 by Fukuma, Shogo
L ung cancer is the leading cause of cancer death globally [1].  Previous studies have revealed the 
usefulness of contrast enhanced computed tomography 
(CT) and dynamic CT for the prediction of tumor 
benignity of solitary pulmonary nodules (SPN) [2-5].  
However,  in contrast to the liver [6],  kidneys [7],  and 
pancreas [8],  no study has focused on differentiating 
among primary lung cancer types using contrast 
enhanced dynamic CT.  In this study,  we explored the 
enhancement patterns of each type of primary lung can-
cer using 2-phase lung dynamic CT to clarify the diag-
nostic capacity of this modality for predicting the 
pathological types of non-small cell lung carcinomas 
(NSCLCs).  In addition,  we assessed the enhancement 
pattern of small cell lung carcinomas (SCLCs).
Material and Methods
Study populations. This was a single-center ret-
rospective analysis performed using data for 217 
patients (128 male,  89 female; age range: 37-92 years) 
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The aim of this study was to explore enhancement patterns of different types of primary lung cancers on 
2-phase dynamic computed tomography (CT).  This study included 217 primary lung cancer patients (141 ade-
nocarcinomas [ADs],  48 squamous cell carcinomas [SCCs],  20 small cell lung carcinomas [SCLCs],  and 8 oth-
ers) who were examined using a 2-phase dynamic scan.  Regions of interest were identified and mean enhance-
ment values were calculated.  After excluding the 20 SCLCs because these lesions had different clinical stages 
from the other cancer types,  the mean attenuation values and subtractions between phases were compared 
between types of non-small cell lung carcinomas (NSCLCs) using the Kruskal–Wallis test.  Late phase attenua-
tion and attenuation of the late minus unenhanced phase (LMU) of SCCs were significantly higher than those of 
ADs (p< 0.05).  To differentiate SCC and AD in the late phase,  a threshold of 80.21 Hounsfield units (HU) gave 
52.9% accuracy.  In LMU,  a threshold of 52.16 HU gave 59.3% accuracy.  Dynamic lung CT has the potential to 
aid in differentiating among NSCLC types.
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who were seen at our institution from July 2013 to 
September 2017; the data were taken from a medical 
database at our institution.  Inclusion criteria were as 
follows: minimum age of 20 years,  pathological diag-
nosis of primary lung cancer untreated before CT scan-
ning,  and no treatment prior to diagnosis.  Patients 
diagnosed with other malignancies within 5 years 
before CT acquisition were excluded.  Lesions not 
described as a nodule using mediastinal window set-
tings (window width: 350 HU [Hounsfield units];  
window center: 30 HU) were also excluded.  Patients 
with multiple lesions were included if the lesions were 
considered histologically homogenous,  in which case 
we measured the largest lesion.  All lesions were histo-
logically diagnosed.  Our institutional research board 
approved this retrospective study (approval number:  
1809-017) and all patients were given an opportunity to 
opt out of the study.
CT Examination. All CT examinations were per-
formed using five helical CT scanners: Aquilion 
Precision (Toshiba Medical Systems,  Otawara,  Japan;  
n = 6),  Aquilion One ViSION Edition (Toshiba Medical 
Systems; n = 148),  Aquilion 64 (Toshiba Medical 
Systems; n=10),  SOMATOM Definition Flash (Systems 
AG,  Forchheim,  Germany; n = 2) and Discovery 
CT750 HD (GE Healthcare,  Milwaukee,  WI,  USA;  
n = 51).  Images were obtained while patients held their 
breath using the following parameters: 120 kVp;  
300 mA or auto mA mode; section thickness: 5 mm.  
All studies consisted of 3 scans.  After an unenhanced 
scan,  a 2-phase dynamic scan was performed at 30 sec 
(early phase) and 90 sec (late phase) after intravenous 
injection of 2.0 ml/kg (maximum of 150 ml) contrast 
medium.
Image analysis. Two radiologists (S.F. and T.S.) 
who were not aware of the diagnosis of lung cancer type 
reviewed the unenhanced and dynamic CT scans.  They 
were instructed to review images using mediastinal 
window settings and were permitted to adjust the 
parameters as needed.  Maximum tumor diameter was 
measured using the following lung window conditions:  
window width: 1,500 HU; window center: −600 HU.  
Multiplanar reformatting was used to achieve more pre-
cise diameter measurements.  A round region of interest 
(ROI) was placed on the most enhanced part of the 
tumor (mean size ± SD [standard deviation]: 16.51 ±  
18.35 mm2; range: 0.86-258.38 mm2).  Edges of the 
nodule were avoided to prevent partial volume effects.  
Vessels,  calcifications,  and necrotic areas were avoided.  
The mean enhancement value within the ROI was cal-
culated.  For evaluating the uniformity of enhancement 
timing,  round ROIs (mean size ± SD: 311.79 ± 79.62 
mm2; range: 115.68-676.13 mm2) were placed in the 
descending aorta at the level of bifurcation of the tra-
chea,  and mean HU values in each phase were calcu-
lated.  Two radiologists were appointed to take these 
measurements.  If they disagreed,  the final decision was 
reached by consensus.
Statistical analysis. Statistical analysis was per-
formed using IBM SPSS Statistics version 22 (IBM,  
Armonk,  NY,  USA).  Statistical significance was set at 
p < 0.05.  First,  we compared the clinical characteristics 
of patients using the Kruskal–Wallis test.  Second,  we 
compared the mean attenuation values of each type of 
NSCLC on each phase and subtractions of each phase 
using the Kruskal–Wallis test.  Subtractions consisted of 
the early phase minus unenhanced phase (EMU),  late 
phase minus unenhanced phase (LMU),  and late phase 
minus early phase (LME).  Receiver operating charac-
teristic (ROC) curve analysis was used to determine HU 
thresholds for suitable sensitivity and specificity to dif-
ferentiate histological types.  The accuracy and area 
under the curve (AUC) were calculated to evaluate the 
diagnostic capacity of the determined threshold.
Results
Patients and tumor characteristics. A total of 
217 lesions from 217 patients met the inclusion criteria.  
The histological types were 141 ADs,  48 SCCs,  20 
SCLCs,  and 8 other carcinomas (4 adenosquamous,  2 
large-cell neuroendocrine,  1 large-cell,  and 1 spindle- 
cell tumor).  Seven AD patients had multiple pulmonary 
nodules that were considered homogenous.  The mean 
of the maximum tumor diameter ± SD was 31.1 ± 17.1  
mm; range: 7.1-111.1 mm (AD: 29.3±14.6 mm; SCC:  
29.6 ±13.2 mm; SCLC: 46.3 ± 27.8 mm; other: 33.3 ±  
27.8 mm).  The lesions consisted of 20 partly solid nod-
ules (all AD) and 197 solid nodules.  A typical lesion is 
shown in Fig.1.  The mean number of days ± SD between 
the CT acquisition and histological sampling or surgery 
was 17.9 ± 19.1 days (range: −37-152 days).
Enhancement pattern of the tumor and aorta. In 
the present study,  the tumor enhancements of all types 
showed a progressive enhancement pattern.  The mean 
enhancements of each type are shown in Table 1 and 
130 ????????????? ????????? ????????????? ???? ???? ??
Fig. 2.
The clinical information of each group is shown in 
Table 2.  Obvious differences were observed in the 
patient characteristics between SCLC and the other 
types of lung cancer,  especially regarding the clinical 
stage.  For this reason,  we considered that it was not 
appropriate to compare SCLC and the other types of 
lung cancer.  We therefore limited our comparison to 
the types of non-small cell lung carcinomas (NSCLCs),  
and analyzed the enhancement pattern of SCLC inde-
pendently.
The mean aortic attenuation value of SCLC was 
302.6 HU,  and that of NSCLC was 320.1 HU in the 
early phase (p = 0.088).  In the late phase,  the mean aor-
tic attenuation value of SCLC was 140.8 HU and that of 
NSCLC was 150.5 HU (p = 0.051).  The weights of 
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????? ?　 The mean attenuation values of types, of total lesions,  and of non-small cell lung carcinoma (NSCLC)
AD
(HU)＊
SCC
(HU)＊
SCLC
(HU)＊
Other
(HU)＊
NSCLC
(HU)＊
Total
(HU)＊
Unenhanced 30.95
(±12.04)
33.94
(±11.67)
37.31
(±10.57)
35.97
(±11.90)
31.88
(±11.99)
32.38
(±11.94)
Early 70.44
(±23.32)
75.40
(±15.52)
64.87
(±13.17)
82.86
(±21.74)
72.16
(±21.74)
71.48
(±21.18)
Late 80.95
(±20.92)
92.01
(±15.29)
68.55
(±20.61)
90.00
(±20.90)
84.01
(±20.21)
82.59
(±20.69)
Early — unenhanced 39.49
(±20.41)
41.46
(±17.52)
27.56
(±11.45)
46.89
(±16.21)
40.27
(±19.57)
39.10
(±19.30)
Late — unenhanced 50.00
(±16.52)
58.07
(±16.65)
31.24
(±17.99)
54.04
(±20.13)
52.13
(±16.97)
50.20
(±18.06)
Late — early 10.51
(±18.13)
16.61
(±13.65)
3.69
(±18.46)
7.15
(±24.35)
11.86
(±17.56)
11.10
(±17.76)
HU,  Hounsfield unit; AD,  adenocarcinoma; SCC,  squamous cell carcinoma; SCLC,  small cell lung carcinoma; NSCLC,  non-small cell 
lung carcinoma.
＊Data is expressed as mean ± standard deviation.
???? ?　 A 67-year-old woman with primary lung adenosquamous carcinoma in the left lower lobe.  (A) A lobulated and speculated nodule 
with a maximum diameter of 17.2 mm.  The maximum average Hounsfield unit (HU) measurements were 51.0 HU in the unenhanced phase 
(B),  112.5 HU in the early phase (C),  and 103.9 HU in the late phase (D).  Thirty-three days after this scan,  a left lower lobectomy was 
performed along with pathological diagnosis.
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???? ?　 Mean attenuation value of tumors in each phase of each type.  Error bars show the standard deviation.
????? ?　 Clinical information of patients with each histological type
AD
(n＝141)
SCC
(n＝48)
SCLC
(N＝20)
Others
(n＝8)
Sex (n)
Male/Female 68/73 42/6 13/7 5/3
Age (y)
Median/range 69/42-92 72.5/37-91 68/54-82 66/44-78
Smoking history (n)
Past or current/Never 81/60 45/3 19/1 7/1
Final diagnostic method (n)
Surgical resection 140 48 3 7
Percutaneous biopsy 0 0 3 0
Bronchoscopy 1 0 14 1
Patients with
multiple lesions (n) 7 0 0 0
Maximum tumor diameter (mm)＊ 29.3 (±14.6) 29.6 (±13.2) 46.3 (±27.8) 33.3 (±27.8)
Clinical stage
　I 95 32 3 4
　II 35 9 2 1
　III 10 7 6 2
　IV 1 0 9 1
The breakdown of patients by clinical stage was based on the eighth edition of the “TNM classification of malignant tumors” published by 
the Union for International Cancer Control,  which is widely used for classification.
AD,  adenocarcinoma; SCC,  squamous cell carcinoma; SCLC,  small cell lung carcinoma; SD,  standard deviation.
＊Data expressed as mean ± standard deviation.
patients at CT acquisition ± SD were 59.18 ± 11.01 kg in 
the NSCLC group,  and 62.28 ± 14.40 kg in the SCLC 
group (p = 0.536,  Mann–Whitney U test).
Adenocarcinoma vs. squamous cell carcinoma.
Kruskal–Wallis analysis revealed there was no signifi-
cant difference in age and maximum tumor diameter 
among the different types of NSCLC (p = 0.064,  0.758,  
respectively).  Only sex was significantly different 
among NSCLC types (p < 0.001),  with the percentage of 
females being significantly higher in the AD than the 
SCC group according to the Dunn–Bonferroni post hoc 
analysis (p < 0.001).  Attenuation of SCC was signifi-
cantly higher than that of AD in the late phase and LMU 
(p < 0.05) (Table 3).  Attenuation thresholds and AUC 
were calculated by ROC analysis (Table 4 and Fig. 3).  
For the late phase,  a threshold of 80.21 HU gave 79.2% 
sensitivity,  44.0% specificity,  and 52.9% accuracy.  For 
the LMU,  a threshold of 52.16 HU gave 60.4% sensitiv-
ity,  58.9% specificity,  and 59.3% accuracy.  A combina-
tion of both criteria gave 56.3% sensitivity,  63.8% spec-
ificity,  and 61.9% accuracy.  Mean attenuation values of 
the aorta between AD and SCC were not significantly 
different in either the early phase or late phase 
(Kruskal–Wallis test,  p = 0.301 and 0.927,  respectively).
Discussion
Contrast enhanced CT [2] and dynamic CT [3-5] are 
useful for predicting tumor benignity of SPNs.  
However,  few studies have used CT to differentiate 
among lung cancer types.  While non-contrast enhanced 
CT [9-11] and contrast enhanced CT [12] have been 
used to differentiate lung cancer types,  no studies have 
assessed the diagnostic capacity of dynamic CT.
We found that the enhancement patterns of each 
type were progressive.  A study by Jeong et al.  [3] cate-
gorized the enhancement patterns of 107 SPNs from 
30 sec to 15 min and found that AD (n=33),  SCC (n=3),  
and SCLC (n = 1) all showed wash-in and wash-out pat-
terns.  In their study,  the time-to-peak enhancement of 
malignant nodules was 3.2 ± 2.7 min.  The progressive 
enhancement patterns within 90 sec observed in our 
study may reflect this “wash-in” phase.  The difference 
between the peak- and pre-enhancement value of malig-
nant nodules reported by Jeong et al.  was 50 ± 16.7 HU 
[3],  similar to our LMU result of 50.20 ± 18.06 HU.
?????????? ????????????????????????????????????? 133
????? ?　 Statistical comparisons of the mean attenuation values of adenocarcinoma (AD),  squamous cell carcinoma (SCC),  and other 
cancer types in each phase using the Kruskal‒Wallis test and post hoc Dunn‒Bonferroni test
Kruskal‒Wallis
test
significance
Post-hoc analysis significance
AD vs SCC AD vs Other SCC vs Other
Unenhanced 0.256　
Early 0.056　
Late 0.004＊ 0.003＊ 1.000 1.000
Early — Unenhanced 0.370　
Late — Unenhanced 0.037＊ 0.031＊ 1.000 1.000
Late — Early 0.017＊ 0.051　 0.621 0.074
AD,  adenocarcinoma; SCC,  squamous cell carcinoma; HU,  Hounsfield unit; vs,  versus.
＊p＜0.05.
????? ?　 ROC Analysis of the diagnostic capacity for differentiating squamous cell carcinoma (SCC) from adenocarcinoma (AD)
Attenuation
threshold
value (HU)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%) AUC
Differentiation of SCC from AD
　　Late 80.21 79.2 44.0 32.5 86.1 52.9 0.661
　　Late — unenhanced 52.16 60.4 58.9 33.3 81.4 59.3 0.625
SCC,  squamous cell carcinoma; AD,  adenocarcinoma; HU,  Hounsfield unit; PPV,  positive predictive value; NPV,  negative predictive 
value; AUC,  area under the curve.
We also found that the enhancement of SCC was 
higher than that of AD in the late phase and LMU.  
Thresholds of 80.21 HU in the late phase and 52.16 HU 
in LMU resulted in AUCs of 0.661 and 0.625,  respec-
tively.  Combining the 2 parameters increased the accu-
racy to 61.9%.  For comparison,  E L et al.  [10] and Zhu 
et al.  [11] used a radiomics approach and reported 
AUCs of 0.655 and 0.893 for samples of 88 AD/93 SCC,  
and 53 AD/76 SCC,  respectively.  Ferreira Junior et al.  
[12] reported an AUC of 0.81 using a radiomics approach 
to contrast enhanced CT for 30 AD and 15 SCC.  These 
differences could have arisen from the different num-
bers of patients,  training datasets,  or methods of fea-
ture selection.  Although the AUC using our dynamic 
CT method was lower than the AUCs for these prior 
studies,  our method was significantly effective for dif-
ferentiating between AD and SCC.  Future research 
should combine dynamic CT and radiomics to improve 
the diagnostic capacities.
Finally,  SCLCs showed relatively low attenuation 
values when compared with NSCLCs in this study.  
However,  the clinical stage of SCLCs was higher than 
that of the other types in our cohort,  which made it 
difficult to compare SCLCs with the other types in this 
study.  Additional studies of larger cohorts under a uni-
form clinical background might reveal the true clinical 
impact of the enhancement of SCLCs in dynamic CT.  
Further,  the aortic enhancement of SCLCs did not differ 
significantly from that of NSCLCs; however,  the for-
mer enhancement did have a lower value,  which may 
have affected the enhancement of SCLCs.  There are 
some other factors which may partly explain the lower 
aortic enhancement of SCLCs.  First,  our patients with 
SCLCs tended to be heavier than our patients with 
NSCLCs,  although the difference was not statistically 
significant.  Second,  a previous study reported that a 
flow rate of 2 mL/sec was associated with insufficient 
contrast enhancement of the pulmonary artery,  
whereas the enhancement at a flow rate of 3 mL/sec was 
associated with lower frequency of insufficient contrast 
enhancement [13].  In this study,  we used a flow rate of 
2 mL/sec,  which might have led to the insufficient con-
trast enhancements in this study.
Our retrospective study had several limitations that 
could have influenced the results.  First,  we did not 
match the clinical characteristics of patients between 
cancer types.  The SCLCs showed a higher clinical stage 
in our cohort,  which made it difficult to compare them 
with the other cancer types in this study.  In addition,  
the AD group had a significantly higher ratio of females 
than the SCC group.  Second,  there were variations in 
the CT equipment used to collect the data.  Third,  the 
section thickness of 5 mm may have been too thick to 
evaluate lung nodules.  However,  we tried to avoid the 
partial volume effect as much as possible.  Fourth,  we 
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???? ?　 ROC curve for discriminating adenocarcinoma from squa-
mous cell carcinoma in the late phase (A) and subtraction of the late 
and unenhanced phase (B).
did not investigate the pathological backgrounds,  
although they could have contributed to the difference 
of enhancement patterns among types.  Previous studies 
indicated a relationship between the enhancement of 
lung tumors and their histological characteristics,  such 
as microvessel density,  vascular endothelial growth fac-
tor (VEGF) staining [14],  and tumor fibrosis [15].  
However,  the histological factors that can explain the 
differences in enhancement between tumor types are 
still unknown,  so further studies on radiological- 
pathological correlations,  such as those discussed 
above,  will be needed to clarify this matter.  Finally,  we 
did not explore the diagnostic capacity of dynamic lung 
CT for the other types of lung cancer.
In conclusion,  dynamic lung CT has the potential to 
aid in differentiating among primary lung cancer types,  
especially by using the late phase.
References
 1.  Dela Cruz CS,  Tanoue LT and Matthay RA: Lung cancer: epide-
miology,  etiology,  and prevention.  Clin Chest Med (2011) 32:  
605-644.
 2.  Swensen SJ,  Viggiano RW,  Midthun DE,  Müller NL,  Sherrick A,  
Yamashita K,  Naidich DP,  Patz EF,  Hartman TE,  Muhm JR and 
Weaver AL: Lung nodule enhancement at CT: multicenter study.  
Radiology (2000) 214: 73-80.
 3.  Jeong YJ,  Lee KS,  Jeong SY,  Chung MJ,  Shim SS,  Kim H,  
Kwon OJ and Kim S: Solitary pulmonary nodule: characterization 
with combined wash-in and washout features at dynamic multi-de-
tector row CT.  Radiology (2005) 237: 675-683.
 4.  Khanduri S,  Bhagat S,  Shokeen P,  Kumar G,  Khanduri S and 
Singh B: Rationale of Using Dynamic Imaging for Characterization 
of Suspicious Lung Masses into Benign or Malignant on Contrast 
Enhanced Multi Detector Computed Tomography.  J Clin Imaging 
Sci (2017) 7: 24.
 5.  Ye XD,  Ye JD,  Yuan Z,  Li WT and Xiao XS: Dynamic CT of soli-
tary pulmonary nodules: comparison of contrast medium distribu-
tion characteristic of malignant and benign lesions.  Clin Transl 
Oncol (2014) 16: 49-56.
 6.  Ariff B,  Lloyd CR,  Khan S,  Shariff M,  Thillainayagam AV,  Bansi 
DS,  Khan SA,  Taylor-Robinson SD and Lim AK: Imaging of liver 
cancer.  World J Gastroenterol (2009) 15: 1289-1300.
 7.  Kim JK,  Kim TK,  Ahn HJ,  Kim CS,  Kim KR and Cho KS:  
Differentiation of subtypes of renal cell carcinoma on helical CT 
scans.  AJR Am J Roentgenol (2002) 178: 1499-1506.
 8.  Low G,  Panu A,  Millo N and Leen E: Multimodality imaging of 
neoplastic and nonneoplastic solid lesions of the pancreas.  
Radiographics (2011) 31: 993-1015.
 9.  Jiang B,  Takashima S,  Miyake C,  Hakucho T,  Takahashi Y,  
Morimoto D,  Numasaki H,  Nakanishi K,  Tomita Y and Higashiyama 
M: Thin-section CT findings in peripheral lung cancer of 3 cm or 
smaller: are there any characteristic features for predicting tumor 
histology or do they depend only on tumor size? Acta Radiol (2014) 
55: 302-308.
10.  E L,  Lu L,  Li L,  Yang H,  Schwartz LH and Zhao B: Radiomics for 
Classification of Lung Cancer Histological Subtypes Based on 
Nonenhanced Computed Tomography.  Acad Radiol (2019) 26:  
1245-1252.
11.  Zhu X,  Dong D,  Chen Z,  Fang M,  Zhang L,  Song J,  Yu D,  Zang 
Y,  Liu Z,  Shi J and Tian J: Radiomic signature as a diagnostic 
factor for histologic subtype classification of non-small cell lung 
cancer.  Eur Radiol (2018) 28: 2772-2778.
12.  Ferreira Junior JR,  Koenigkam-Santos M,  Cipriano FEG,  Fabro AT 
and Azevedo-Marques PM: Radiomics-based features for pattern 
recognition of lung cancer histopathology and metastases.  Comput 
Methods Programs Biomed (2018) 159: 23-30.
13.  Ozawa Y,  Hara M and Shibamoto Y: The frequency of insufficient 
contrast enhancement of the pulmonary artery in routine contrast- 
enhanced chest CT and its improvement with an increased injec-
tion rate: a prospective study.  J Thorac Imaging (2011) 26: 42-47.
14.  Yi CA,  Lee KS,  Kim EA,  Han J,  Kim H,  Kwon OJ,  Jeong YJ and 
Kim S: Solitary pulmonary nodules: dynamic enhanced multi-de-
tector row CT study and comparison with vascular endothelial 
growth factor and microvessel density.  Radiology (2004) 233:  
191-199.
15.  Iwano S,  Koike W,  Matsuo K,  Okada T,  Shimoyama Y and 
Naganawa S: Correlation between dual-phase dynamic multi-de-
tector CT findings and fibrosis within lung adenocarcinoma tumors.  
Eur J Radiol (2011) 80: e470-475.
?????????? ????????????????????????????????????? 135
